Literature DB >> 17297425

Biliary secretion and excretion in health and disease: current concepts.

Alan F Hofmann1.   

Abstract

Biliary secretion in health and disease is reviewed. The powerful techniques of molecular biology have enabled cloning of the transporters involved in biliary secretion and the enterohepatic circulation of bile acids. This, in turn has permitted elucidation of their function as well as their regulation by nuclear receptors. Bile acid secretion is required for efficient lipid absorption, and bile acids also possess powerful direct and indirect antimicrobial functions in the small intestine. The enterohepatic circulation results from efficient ileal absorption, and is highly regulated at two sites. In the hepatocyte, biosynthesis of bile acids is regulated in negative feedback manner by the nuclear receptor FXR as well as by cytokines and by a peptide (FGF-19) liberated by bile acids from the ileal enterocyte. In the ileal enterocyte, bile acid reclamation is regulated in negative feedback manner by FXR and other nuclear receptors. The bile salt export pump (BSEP) mediates uphill canalicular bile acid secretion. Inborn defects in its function cause intrahepatic cholestasis in infants; inhibition of its function by drugs causes hepatotoxicity. Bile acid therapy is based on correction of bile acid deficiency by supplemental bile acids or displacement in which a noncytotoxic bile acid (ursodeoxycholic acid, ursodiol, UDCA) is administered and dilutes out the endogenous cytotoxic bile acids. Administration of primary bile acids may be lifesaving in inborn defects of bile acid biosynthesis. A synthetic bile acid, norUDCA is absorbed by the biliary ductules after secretion and cures the peribiliary fibrosis occurring in the MDR2-/- mouse which lacks biliary phospholipid.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17297425

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  34 in total

1.  Concept of the pathogenesis and treatment of cholelithiasis.

Authors:  Vasiliy Ivanovich Reshetnyak
Journal:  World J Hepatol       Date:  2012-02-27

2.  Ursodeoxycholic Acid Inhibits Clostridium difficile Spore Germination and Vegetative Growth, and Prevents the Recurrence of Ileal Pouchitis Associated With the Infection.

Authors:  Alexa R Weingarden; Chi Chen; Ningning Zhang; Carolyn T Graiziger; Peter I Dosa; Clifford J Steer; Megan K Shaughnessy; James R Johnson; Michael J Sadowsky; Alexander Khoruts
Journal:  J Clin Gastroenterol       Date:  2016-09       Impact factor: 3.062

Review 3.  Physiological and molecular biochemical mechanisms of bile formation.

Authors:  Vasiliy Ivanovich Reshetnyak
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

Review 4.  Physiology of bile secretion.

Authors:  Alejandro Esteller
Journal:  World J Gastroenterol       Date:  2008-10-07       Impact factor: 5.742

5.  Crosstalk of liver, bile ducts and the gut.

Authors:  Ulrich Beuers
Journal:  Clin Rev Allergy Immunol       Date:  2009-02       Impact factor: 8.667

6.  Tauroursodeoxycholic acid attenuates progression of steatohepatitis in mice fed a methionine-choline-deficient diet.

Authors:  Eun-Ju Cho; Jung-Hwan Yoon; Min-Sun Kwak; Eun Sun Jang; Jeong-Hoon Lee; Su Jong Yu; Yoon Jun Kim; Chung Yong Kim; Hyo-Suk Lee
Journal:  Dig Dis Sci       Date:  2014-05-28       Impact factor: 3.199

Review 7.  Fifty years of advances in bile acid synthesis and metabolism.

Authors:  David W Russell
Journal:  J Lipid Res       Date:  2008-09-24       Impact factor: 5.922

Review 8.  Bile acid transporters in health and disease.

Authors:  A Kosters; S J Karpen
Journal:  Xenobiotica       Date:  2008-07       Impact factor: 1.908

9.  Identification of mutation-prone points in bile salt export pump.

Authors:  Viroj Wiwanitkit
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

Review 10.  Bile acids: emerging role in management of liver diseases.

Authors:  Amon Asgharpour; Divya Kumar; Arun Sanyal
Journal:  Hepatol Int       Date:  2015-08-29       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.